Home › Lung Cancer › Pennsylvania

Lung Cancer clinical trials in Pennsylvania

57 studies for Lung Cancer are looking for participants at sites in Pennsylvania.

Cities in Pennsylvania

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Lehigh Valley Hospital-Cedar Crest, Allentown
Lehigh Valley Hospital - Muhlenberg, Bethlehem
Bryn Mawr Hospital, Bryn Mawr
and 14 more

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06498635

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Lehigh Valley Hospital-Cedar Crest, Allentown
UPMC Altoona, Altoona
UPMC-Heritage Valley Health System Beaver, Beaver
and 53 more

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04267848

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Penn State Milton S. Hershey Medical Center-Penn State Cancer Institute ( Site 0059), Hershey
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312137

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Alliance Cancer Specialists - Media, Media
Guthrie Medical Group, Sayre

RecruitingPhase 3

Ages 18 to 100 · All sexes · Updated Sep 25, 2026 · NCT05920356

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Lehigh Valley Hospital-Cedar Crest, Allentown
Lehigh Valley Hospital - Muhlenberg, Bethlehem
Bryn Mawr Hospital, Bryn Mawr
and 12 more

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04181060

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Bryn Mawr Hospital, Bryn Mawr
Penn State Milton S Hershey Medical Center, Hershey
Riddle Memorial Hospital, Media
and 6 more

RecruitingPhase 3

Ages 70 and older · All sexes · Updated Sep 24, 2026 · NCT06096844

A Registry for People With Lung Cancer

Thomas Jefferson University Hospital (Data Collection Only), Philadelphia
ALLEGHENY HEALTH NETWORK (Data Collection Only), Pittsburgh

RecruitingObservational study

Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06424327

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Pittsburgh

RecruitingPhase 2

Ages 18 to 95 · All sexes · Updated Sep 23, 2026 · NCT05061550

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Hospital of the University of Pennsylvania, Philadelphia
West Penn Allegheny Health, Pittsburgh

RecruitingPhase 2/3

Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07100080

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Allegheny Health Network, Pittsburgh

RecruitingPhase 1/2

Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

UPMC Hillman Cancer Center, Pittsburgh

RecruitingPhase 1/2

Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06287775

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Abramson Cancer Center of the University of Pennsylvania, Philadelphia
University of Pittsburgh Medical Center, Pittsburgh
WellSpan York Cancer Center, York

RecruitingPhase 1/2

Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

St. Luke's University Health Network, Bethlehem
Allegheny Cancer Center, Pittsburgh
Reading Hospital - McGlinn Cancer Institute, West Reading

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06793215

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

USO - Alliance Cancer Specialists, PC, Horsham
Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
UPMC Hillman Cancer Center, Pittsburgh

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

UPMC Hillman Cancer Center, Pittsburgh

RecruitingPhase 1/2

Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07012031

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Avenzo Therapeutics Recruiting Site, Philadelphia

RecruitingPhase 1/2

Ages 18 to 75 · All sexes · Updated Sep 4, 2026 · NCT07038343

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Lehigh Valley Hospital-Cedar Crest, Allentown
Lehigh Valley Hospital - Muhlenberg, Bethlehem
Geisinger Medical Center, Danville
and 7 more

RecruitingObservational studyHealthy volunteers welcome

Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Fox Chase Cancer Center, Philadelphia

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT07185997

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

St. Luke's Physician Group - St. Luke's Cancer Care Associates, Fountain Hill

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06712355

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Penn State Milton S. Hershey Medical Center, Hershey

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06881784

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Alliance Cancer Specialists, Sellersville

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT06765109

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

Hospital of the University of Pennsylvania, Philadelphia

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07499674

Pemefolacianine for IMI of Lung Cancer

University of Pennsylvania, Philadelphia

RecruitingPhase 1

Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07772895

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Abramson Cancer Center ( Site 0010), Philadelphia

RecruitingPhase 2

Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06731907

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Christiana Care Health System-Concord Health Center, Chadds Ford
Chambersburg Hospital, Chambersburg
Geisinger Medical Center, Danville
and 17 more

RecruitingPhase 3

Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05624996

Distance-Based Exercise to Preserve Function and Prevent Disability

UPMC Hillman Cancer Center at Butler Health System, Butler
IRMC Cancer Center, Indiana
UPMC Hillman Cancer Center - New Castle, New Castle
and 2 more

Recruiting

Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07059884

Empathic Communication Skills (ECS) Training

University of Pennsylvania (Data Collection Only), Philadelphia
Fox Chase Cancer Center (Data Collection Only), Philadelphia

RecruitingHealthy volunteers welcome

Ages 18 to 100 · All sexes · Updated Jul 23, 2026 · NCT05456841

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

Clinical Research Associates of Central Pennsylvania, DuBois

Recruiting

Ages 50 to 80 · All sexes · Updated Jul 16, 2026 · NCT07168993

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh

RecruitingPhase 1/2

Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06060613

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

UPMC Hillman Cancer Center, Pittsburgh

RecruitingPhase 1

Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07315113

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

UPMC Hillman Cancer Center, Pittsburgh

RecruitingPhase 1/2

Ages 18 and older · All sexes · Updated Jun 30, 2026 · NCT06162221

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Sidney Kimmel Cancer Center, Philadelphia

RecruitingPhase 1

Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07458347

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Allegheny General Hospital, Natrona Heights

RecruitingPhase 2

Ages 18 to 70 · All sexes · Updated Jun 26, 2026 · NCT04614103

MOv19-BBz CAR T Cells in FRa+ Cancers

University of Pennsylvania, Philadelphia

RecruitingPhase 1

Ages 18 and older · All sexes · Updated Jun 18, 2026 · NCT07116057

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

UPMC Hillman Cancer Center, Pittsburgh

RecruitingPhase 1/2

Ages 18 to 70 · All sexes · Updated Jun 11, 2026 · NCT05361174

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

UPMC Altoona, Altoona
UPMC-Heritage Valley Health System Beaver, Beaver
UPMC Hillman Cancer Center at Butler Health System, Butler
and 37 more

RecruitingPhase 2

Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT05642572

Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES

Penn Medicine University City, Philadelphia
Perelman Center for Advanced Medicine, Philadelphia
Penn Medicine Washington Square, Philadelphia

Recruiting

Ages 35 to 89 · All sexes · Updated Jun 2, 2026 · NCT05968898

Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

RecruitingHealthy volunteers welcome

Ages 50 to 77 · All sexes · Updated May 29, 2026 · NCT05679349

Telehealth Collaborative Care Model (CoCM) in Lung Cancer

Abramson Cancer Center at the University of Pennsylvania, Philadelphia

Recruiting

Ages 18 and older · All sexes · Updated May 28, 2026 · NCT07102147

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center, Philadelphia

RecruitingPhase 2

Ages 18 and older · All sexes · Updated May 22, 2026 · NCT05800587

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.